What is solifenacin?

What is Solifenacin?

Solifenacin is a once-daily oral antimuscarinic medication (specifically a competitive muscarinic M3 receptor antagonist) approved by the FDA for treating overactive bladder symptoms including urge urinary incontinence, urgency, frequency, and nocturia. 1

Mechanism of Action

• Solifenacin works by selectively blocking muscarinic M3 receptors in the detrusor muscle of the bladder wall, thereby reducing involuntary bladder contractions that cause overactive bladder symptoms. 2, 3
• The drug demonstrates greater bladder selectivity compared to salivary glands when compared to other antimuscarinics such as tolterodine, oxybutynin, darifenacin, or atropine in preclinical studies, potentially translating to fewer anticholinergic side effects. 3

Clinical Indications and Place in Therapy

• Solifenacin is indicated as second-line therapy for overactive bladder after behavioral therapies (bladder training, pelvic floor muscle training, fluid management) have been tried, as recommended by the American Urological Association. 4
• The medication is effective for all symptoms of overactive bladder, including reduction in urinary incontinence episodes, decrease in urgency episodes, reduction in urinary frequency, and improvement in nocturia. 4
• Solifenacin may be used in combination with tamsulosin for men experiencing both storage and voiding lower urinary tract symptoms. 5

Dosing and Administration

• Solifenacin is available in 5 mg and 10 mg oral tablets, taken once daily with water (with or without food). 1
• The standard starting dose is 5 mg once daily, with the option to increase to 10 mg if needed based on symptom severity and tolerability. 6
• Therapeutic effects typically occur after 2–4 weeks of treatment and are maintained with long-term therapy. 7

Pharmacokinetics

• Solifenacin has approximately 90% oral bioavailability, reaches peak plasma concentrations in 3–8 hours, and has a terminal elimination half-life of 33–85 hours, supporting once-daily dosing. 7
• The drug is primarily metabolized by CYP3A4 in the liver, with only about 7% excreted unchanged in urine. 7
• Solifenacin is highly protein-bound (93–96%) and has a large volume of distribution (600 L), likely crossing the blood-brain barrier. 7

Combination Therapy

• The combination of solifenacin 5 mg plus mirabegron 50 mg has demonstrated superior efficacy to either medication alone in reducing incontinence episodes and micturitions, as recommended by the European Association of Urology. 4
• This specific combination is supported by the SYNERGY I/II and BESIDE trials and represents an effective option for patients who fail monotherapy. 8

Contraindications (Absolute)

• Solifenacin must not be prescribed to patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or known hypersensitivity to solifenacin. 1

Warnings and Precautions

• Use solifenacin with extreme caution in patients with impaired gastric emptying, history of urinary retention, or narrow-angle glaucoma, as advised by the American Urological Association. 4
• The medication may cause angioedema (swelling of tongue, laryngopharynx) requiring immediate discontinuation and emergency care. 1
• Central nervous system effects including drowsiness and blurred vision may occur; patients should exercise caution when driving or operating machinery until the drug's effects are known. 1
• Decreased sweating leading to heat prostration can occur in hot environments. 1

Common Adverse Effects

• The most common side effects include dry mouth (10.9% at 5 mg, 27.1% at 10 mg), constipation (5.3% at 5 mg, 12.9% at 10 mg), and blurred vision (approximately 4.5–4.7%). 9
• Patients should contact their healthcare provider if they experience severe abdominal pain or constipation lasting 3 or more days. 1
• Dry mouth is typically mild and does not compromise the favorable tolerability profile. 6

Dose Adjustments for Special Populations

• For patients with moderate hepatic impairment (Child-Pugh score 7–9) or severe renal impairment (creatinine clearance <30 mL/min), the maximum recommended dose is 5 mg daily. 7
• When coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole), solifenacin exposure increases approximately 2-fold, and the dose should not exceed 5 mg daily. 7
• Elderly patients experience approximately 1.2-fold increased exposure but generally do not require routine dose adjustment unless other risk factors are present. 7

Comparative Efficacy

• Solifenacin 5 or 10 mg once daily was noninferior to tolterodine extended-release 4 mg for reducing urinary frequency and significantly superior for reducing urgency, incontinence, and urge incontinence episodes. 3
• At least half of incontinent patients receiving solifenacin achieved continence by study end in comparative trials. 3

Common Pitfalls to Avoid

• Failing to initiate or continue behavioral therapies alongside solifenacin is a common error; antimuscarinic medications should complement, not replace, non-pharmacologic interventions. 8
• Prescribing solifenacin to patients with absolute contraindications (narrow-angle glaucoma, urinary retention, gastric retention) without proper screening. 4, 1
• Discontinuing solifenacin after inadequate trial duration; a minimum 4–8 week trial is necessary to assess efficacy. 8
• Not considering dose reduction or switching to an alternative agent (such as a beta-3 agonist like mirabegron) when adverse effects occur, rather than abandoning pharmacotherapy entirely. 8